Outcome of BM

Krebs Biochemicals & Industries Limited CIN : L24110AP1991PLC103912 August 6, 2026 To, To, BSE Limited National Stock Exchange of India Ltd P J Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex, Fort, Mumbai- 400 001. Bandra(E), Mumbai- 400 051. Scrip Code : 524518 Scrip Code : KREBSBIO Dear Sir / Madam, Sub: Outcome of Board Meeting – Unaudited Financial Results for the 1st quarter ended 30th June 2026. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following: 1. Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2026. 2. Limited Review Report by the Auditors on the Unaudited Financial Results for the 1st quarter ended June 30, 2026. The Meeting of the Board of Directors commenced at 11:30 am and concluded at 01:30 p.m. The above is for your information and record. Thanking you, Yours Faithfully, For Krebs Biochemicals and Industries Limited Rakesh R Kalbate Company Secretary & Compliance Officer Encl.: a/a. Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Tel : 040-66808040 Website- www.krebsbiochem.com, E-mail - com_sec@krebsbiochem.com